Loading...
Loading...
BLU| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1,431.1M |
| Gross Profit | -1,431.1M |
| Operating Expense | 27.7M |
| Operating I/L | -27.7M |
| Other Income/Expense | 2.7M |
| Interest Income | 3.1M |
| Pretax | -25.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -25.1M |
BELLUS Health Inc. is a clinical stage biopharmaceutical company specializing in the development of therapeutics for refractory chronic cough (RCC) and other cough hypersensitivity indications. Their lead product candidate, BLU-5937, is an antagonist of the P2X3 receptor currently in Phase II clinical trial for the treatment of RCC and chronic pruritus.
